Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVGRNASDAQ:BLACNASDAQ:CHEKNASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$2.97$1.57M1.091.15 million shsN/ABLACBellevue Life Sciences Acquisition$1.16-4.1%$1.52$3.01▼$13.40$4.69M-0.0819,293 shs55,255 shsCHEKCheck-Cap$0.85-0.5%$0.79$0.56▼$3.04$4.96M0.21378,690 shs7,217 shsPSTVPlus Therapeutics$0.30-4.5%$0.76$0.24▼$2.67$5.08M0.884.44 million shs1.39 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-84.01%BLACBellevue Life Sciences Acquisition+7.08%+6.14%-9.02%-71.33%-88.72%CHEKCheck-Cap-0.53%-8.38%+25.94%+11.23%-62.16%PSTVPlus Therapeutics-4.47%-28.81%-69.60%-75.08%-86.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVGRAvingerN/AN/AN/AN/AN/AN/AN/AN/ABLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACHEKCheck-Cap0.5596 of 5 stars0.05.00.00.00.70.00.6PSTVPlus Therapeutics1.0484 of 5 stars3.32.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger 0.00N/AN/AN/ABLACBellevue Life Sciences Acquisition 0.00N/AN/AN/ACHEKCheck-Cap 0.00N/AN/AN/APSTVPlus Therapeutics 2.50Moderate Buy$11.503,746.15% UpsideCurrent Analyst Ratings BreakdownLatest AVGR, PSTV, CHEK, and BLAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.003/28/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.503/17/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$9.00 ➝ $9.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.26M0.22N/AN/A($4.53) per share-0.10BLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AN/ACHEKCheck-CapN/AN/AN/AN/A$4.05 per shareN/APSTVPlus Therapeutics$4.91M1.04N/AN/A($0.30) per share-1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$11.06N/AN/AN/A-261.06%-5,527.11%-123.25%8/6/2025 (Estimated)BLACBellevue Life Sciences AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ACHEKCheck-Cap-$17.57M-$3.00N/A∞N/AN/AN/AN/A6/3/2025 (Estimated)PSTVPlus Therapeutics-$13.32M-$2.50N/AN/AN/A-225.07%N/A-154.56%8/12/2025 (Estimated)Latest AVGR, PSTV, CHEK, and BLAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024PSTVPlus Therapeutics-$0.51-$0.67-$0.16-$0.67$1.19 million$1.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/ABLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/ACHEKCheck-CapN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/A1.210.81BLACBellevue Life Sciences AcquisitionN/AN/AN/ACHEKCheck-CapN/A19.67N/APSTVPlus TherapeuticsN/A0.440.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%BLACBellevue Life Sciences Acquisition55.30%CHEKCheck-Cap1.07%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipAVGRAvinger42.80%BLACBellevue Life Sciences Acquisition33.67%CHEKCheck-Cap0.48%PSTVPlus Therapeutics3.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger703.31 million1.89 millionNot OptionableBLACBellevue Life Sciences AcquisitionN/A4.04 million2.68 millionNot OptionableCHEKCheck-Cap805.85 million5.82 millionNot OptionablePSTVPlus Therapeutics2017.00 million5.57 millionNot OptionableAVGR, PSTV, CHEK, and BLAC HeadlinesRecent News About These CompaniesPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed ...May 23 at 5:31 PM | gurufocus.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-QMay 23 at 4:15 PM | globenewswire.comPlus Therapeutics (PSTV) Expected to Announce Quarterly Earnings on WednesdayMay 19, 2025 | americanbankingnews.comPlus Therapeutics reports progress in CNS cancer therapyMay 15, 2025 | investing.comPlus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)May 15, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 14, 2025 | zacks.comPlus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)May 14, 2025 | globenewswire.comPlus Therapeutics to Participate in the D. Boral Capital Inaugural Global ConferenceMay 8, 2025 | globenewswire.comD. Boral Capital Downgrades Plus Therapeutics (PSTV)May 5, 2025 | msn.comPlus Therapeutics appoints Kyle Guse to board of directorsApril 23, 2025 | markets.businessinsider.com5 Small Drug Stocks to Buy as Tariff-Related Uncertainty LoomsApril 23, 2025 | zacks.comPlus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of DirectorsApril 23, 2025 | globenewswire.comPlus Therapeutics Appoints Kyle Guse to BoardApril 18, 2025 | tipranks.comPlus Therapeutics presents data highlighting clinical benefit, safety of REYOBIQApril 16, 2025 | markets.businessinsider.comPlus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal MetastasesApril 15, 2025 | globenewswire.comPlus (PSTV) Upgraded to Buy: Here's What You Should KnowApril 1, 2025 | zacks.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comPlus Therapeutics price target lowered to $5.50 from $8 at H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comWhy Plus Therapeutics, Inc.’s (PSTV) Stock Is Down 23.03%March 29, 2025 | aaii.comPlus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timelineMarch 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVGR, PSTV, CHEK, and BLAC Company DescriptionsAvinger NASDAQ:AVGR$0.47 0.00 (0.00%) As of 05/23/2025Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Bellevue Life Sciences Acquisition NASDAQ:BLAC$1.16 -0.05 (-4.13%) As of 05/23/2025Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.Check-Cap NASDAQ:CHEK$0.85 0.00 (-0.53%) Closing price 05/23/2025 03:51 PM EasternExtended Trading$0.85 +0.00 (+0.52%) As of 05/23/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.Plus Therapeutics NASDAQ:PSTV$0.30 -0.01 (-4.47%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.30 +0.00 (+1.00%) As of 05/23/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
